In the in vivo tumorigenesis model, the administration of TOPK inhibitor OTS514 enhanced the anticancer effect of 5‐FU, and the combinatory use of OTS514 and KRASG12C inhibitor AMG510 showed synergistic anti‐tumour effect. This evidence concerns the gene PBK and neoplasm.